BTBalamugesh Thangakunam

Balamugesh Thangakunam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Balamugesh Thangakunam has a total of 169 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Isolated Central Nervous System Tuberculosis‐Associated Immune Reconstitution Inflammatory Syndrome—Case Report and Literature Review

    by Mithen Ravisankar, Muniza Bai, Vignesh Kumar Kathiresan, Jefferson Daniel Jawahar, Balamugesh Thangakunam, Angel Miraclin Thirugnanakumar, Elanthenral Sigamani

    An immunocompetent young male in his early 20s presented with a 1‐month history of central chest pain, dyspepsia and significant weight loss. Initial evaluation revealed a large, deep oesophageal ulcer and extensive necrotic mediastinal lymphadenopathy. Endobronchial ultrasound‐guided fine‐needle aspiration of the mediastinal nodes confirmed necrotising granulomatous inflammation, suggestive of tuberculosis. Following initiation of anti‐tuberculosis treatment (ATT), he initially showed systemic improvement. However, within 2 weeks, he developed drug‐induced liver injury along with new‐onset focal neurological deficits, including right‐sided hemiparesis and vocal cord palsy. Neuroimaging revealed multiple new intracranial lesions involving the left temporal lobe, right posterior parietal region and brainstem, whilst repeat cross‐sectional imaging of the chest and abdomen was suggestive of interval improvement. A diagnosis of paradoxical isolated central nervous system tuberculosis‐associated immune reconstitution inflammatory syndrome was made. He was managed with high‐dose systemic corticosteroids and a modified hepatoprotective ATT regimen, resulting in clinical improvement.

  • Open Access

    A multi-country head-to-head accuracy comparison of automated chest X-ray algorithms for tuberculosis

    by William Worodria, Robert Castro, Sandra V Kik, Victoria Dalay, Brigitta Derendinger, Charles Festo, Thanh Quoc Nguyen, Mihaja Raberahona, Swati Sudarsan, Alfred Andama, et al.

    Rationale: Computer-aided detection algorithms for automated chest X-ray reading have been endorsed by the World Health Organization for tuberculosis triage, but independent, multi-country assessment of current products is needed to guide implementation. Objectives: We included chest X-rays from adults who presented to outpatient facilities with at least 2 weeks of cough in India, Madagascar, the Philippines, South Africa, Tanzania, Uganda, and Vietnam. Methods: We calculated and compared the accuracy overall and by country and key groups for 7 computer-aided detection algorithms: CAD4TB, qXR, INSIGHT CXR, DrAid, Genki, InferRead, and Radify. We determined if any computer-aided detection product could achieve the minimum target accuracy for a tuberculosis triage test (≥ 90% sensitivity and ≥ 70% specificity). Results: Of 3901 individuals included, the median age was 41 years (IQR, 29-54 years), 12.9% were people living with HIV, 8.2% were living with diabetes, and 21.2% had a prior history of tuberculosis. Specificity ranged from 30.9% to 73.5% at 90% sensitivity. CAD4TB achieved the highest specificity at 90% sensitivity (73.5% specific [95% CI, 71.9%-75.1%]), although qXR and INSIGHT CXR also achieved the target 70% specificity. There was heterogeneity by country and subgroup that improved with population-specific thresholds, except for people living with HIV, 50 years and older, or with a history of tuberculosis. Conclusions: Multiple computer-aided detection algorithms achieved the minimum target accuracy for a tuberculosis triage test among symptomatic individuals with cough. Further efforts are needed to integrate computer-aided detection into routine tuberculosis case detection programs in high-burden communities.


  • Open Access

    Predictors of depression in asthma patients in an Indian referral hospital

    by Anushka Kataria, Jefferson Daniel, Barney Isaac, Balamugesh Thangakunam, Jesson Paulson Illimoottil, Reka Karuppusami, Devasahayam J. Christopher

    Background: Asthma has been shown to have a significant association with the diagnoses of mental health disorders, including depression; however, information from India is scarce. Objectives: The study aims to estimate the prevalence of depression in asthma patients and identify associated risk factors. Methods: A total of 248 participants aged 18 and above who presented to the pulmonary medicine outpatient clinic of the Christian Medical College, Vellore, Tamil Nadu, India, were recruited. Socio-demographic and clinical details, including treatment compliance were collected, and inhaler technique was assessed. Asthma control was measured by the Asthma Control Test (ACT) and the quality of life by Asthma Quality of Life Questionnaire (AQLQ). The Patient Health Questionnaire-9 (PHQ-9) was used to screen for depression. Logistic regression was used to determine the risk factors for depression. Results: Out of the 248 participants, 24.6% screened positive for depression. Asthma control was worse (ACT 19.07 ± 4.87 vs 21.93 ± 3.66; p < 0.001) and quality of life was poorer (AQLQ 5.53 ± 0.72 vs 6.06 ± 0.63; p < 0.001) in those with depression. There was a low negative correlation (ρ = −0.332, P < 0.001) between ACT score and PHQ-9 score and a moderate negative correlation (ρ = −0.451, P < 0.001) between AQLQ score and PHQ-9 score. Univariate logistic regression analysis showed six independent factors associated with depression: female gender (OR 1.87), presence of one or more comorbidities (OR 2.10), incorrect inhaler technique (OR 3.59), poor compliance with inhaled corticosteroids (ICS) (OR 2.30), poorly controlled asthma (ACT) (OR 2.92) and lower AQLQ score (OR = 0.32). Multivariate logistic regression analysis revealed that the AQLQ was the only independent risk factor for depression (OR 0.27, P = 0.001). Conclusion: Adult asthma patients in this Indian cohort showed a high prevalence of depression. The study highlights key risk factors for depression in asthma and reiterates the need to screen asthma patients for depression.


  • Open Access

    A retrospective analysis of the diagnostic utility of endobronchial ultrasound guided–intranodal forceps biopsy (EBUS-IFB) in the evaluation of mediastinal adenopathy

    by Richu Bob Kurien, Priya Nadesan, Balamugesh Thangakunam, Barney Isaac, Thomas Alex Kodiatte, Reka Karuppusami

    Background: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is the preferred diagnostic modality for evaluating mediastinal lymphadenopathy. However, its diagnostic yield is significantly reduced in conditions such as sarcoidosis, tuberculosis, and lymphoma. To address this limitation, EBUS-guided intranodal forceps biopsy (EBUS-IFB) has been proposed as an adjunct technique to enhance diagnostic accuracy in these challenging cases. This study aimed to evaluate the diagnostic yield of EBUS-IFB in the assessment of mediastinal lymphadenopathy. Methods: We retrospectively reviewed patients with mediastinal lymphadenopathy who underwent EBUS-guided intranodal forceps biopsy (EBUS-IFB). Diagnostic yield was determined using a composite reference standard (CRS), which was considered positive if a definitive diagnosis was established by any of the following: rapid on-site evaluation (ROSE), EBUS-TBNA, EBUS-IFB, bronchial biopsy, or transbronchial lung biopsy. To specifically evaluate the incremental diagnostic yield of EBUS-IFB, cases with non-diagnostic ROSE results were analysed separately. Results: Of the 40 cases with undiagnosed mediastinal lymphadenopathy, CRS was obtained in 31 cases (77.5%), while the remainder were diagnosed as reactive lymphadenopathy. Sampling adequacy was achieved in 39 out of 40 cases (97.5%). The overall diagnostic yield for EBUS-TBNA, EBUS-IFB, and combined EBUS-TBNA along with IFB (combined approach) were 54.8%, 83.9% (p value:0.03), and 90.3% (p value: 0.004) respectively. The additional diagnostic yield for EBUS-IFB and the combined approach (EBUS-TBNA + IFB) were 29.0% and 35.5% respectively, as compared to EBUS-TBNA alone. The sensitivity and specificity EBUS-IFB were 84% and 100% respectively. In subgroup analysis for cases with non-diagnostic ROSE, the diagnostic yield for EBUS-TBNA, EBUS-IFB, and the combined approach (EBUS-TBNA + IFB) were 48.2%, 85.2% (p value: 0.009) and 88.9% (p value: 0.003) respectively. The additional diagnostic yield for EBUS-IFB and the combined approach (EBUS-TBNA + IFB) were 37.0% and 40.7% respectively, as compared to EBUS-TBNA alone. The sensitivity and specificity of EBUS-IFB when ROSE was non-diagnostic were 85.2% and 100% respectively. No major complications were noted. Conclusion: The addition of IFB to routine TBNA significantly improves the diagnostic yield of EBUS, particularly in cases of non-diagnostic ROSE, with no added procedural complications.

  • Role of Endobronchial Ultrasound in the Developing World

    by Balamugesh Thangakunam

    In developing countries, endobronchial ultrasound (EBUS) bronchoscopy is increasingly used for the evaluation of thoracic malignancy and mediastinal adenopathy. Although “blind” transbronchial needle aspiration (TBNA) is more readily available in resource-limited regions and the TBNA yield is good in suitably selected cases, EBUS bronchoscopy is becoming more popular and accessible in these regions now. Compared to the developed countries, a higher proportion of lung and mediastinal pathology may be due to infections (e.g., tuberculosis). EBUS-TBNA is useful with high diagnostic yields in atypical infections too. In view of its higher costs, EBUS may be used judiciously and is particularly suitable in settings where other diagnostic options have either been exhausted or are unsuitable.

  • Open Access

    Forty-steps desaturation test does not have prognostic value in COVID-19 due to omicron variant

    by Balamugesh Thangakunam, Barney Isaac, Rajasekar Sekar, Kundavaram Paul Prabhakar Abhilash, Mathew Varghese Nellimootil, Hema Paul, Devasahayam Jesudas Christopher

  • Real-World Outcomes of Induction Chemotherapy With or Without Low-Dose Nivolumab for Stage III Non–Small Cell Lung Cancer Ineligible for Up-Front Local Therapy: A Propensity Score–Matched Analysis

    by Praveen Kumar Marimuthu, Josh Thomas Georgy, Deepa Susan Joy Philip, Ajoy Oommen John, Anjana Joel, Divya Bala Thumaty, Raju Titus Chacko, Prashant Jambunathan, Zachariah Thomas, Kovilapu Harikrishna, et al.

    PURPOSE: There is a lack of literature on treating stage III non–oncogene-driven non–small cell lung cancer (NSCLC) with low-dose immunotherapy in combination with chemotherapy for patients who are not candidates for local therapy up front. MATERIALS AND METHODS: We performed an institutional retrospective analysis of patients with stage III non–oncogene-driven NSCLC deemed ineligible for up-front local therapy. The NACT + I/O group comprised those who received induction chemotherapy in combination with low-dose nivolumab, and the NACT-alone group comprised those who received chemotherapy alone. Propensity score matching was performed based on stage, histology, and respiratory comorbid status. The primary end point was objective response rate (ORR). Secondary end points were conversion rates to local therapy, progression-free survival (PFS), overall survival (OS), and Grade ≥3 adverse events. RESULTS: Eighty-two patients were equally divided into the NACT + I/O and NACT-alone groups. The most common histology was squamous cell (60%), followed by adenocarcinoma (34%) and mixed (5%). Majority (85%) had stage IIIB or IIIC disease. The ORR to induction was 73.1% (complete response 1, partial response [PR] 29, stable disease [SD] 10, progressive disease [PD] 1) in the NACT + I/O group versus 39% (PR-16, SD-13, PD-12) in the NACT-alone group ( P = .002). The NACT + I/O group had a higher proportion of patients undergoing sequential local therapy (66% v 46.3%, P = .075), a better median PFS (not reached [NR] v 11 months, P = .0014), and median OS (NR v 28 months, P = .22) compared with the NACT-alone group at a median follow-up of 13.5 months. There were no new safety signals identified. CONCLUSION: Adding low-dose immunotherapy to chemotherapy improved ORRs, conversion rates to local therapy, and PFS in patients with stage III non–oncogene-driven NSCLC, who were ineligible for up-front local therapy.

  • Open Access

    Diagnostic Accuracy of Tuberculosis Screening Tests in a Prospective Multinational Cohort: Chest Radiography With Computer-Aided Detection, Xpert Tuberculosis Host Response, and C-Reactive Protein

    by Rebecca Crowder, Balamugesh Thangakunam, Alfred Andama, Devasahayam J Christopher, Victoria Dalay, Welile Nwamba, Sandra V Kik, Dong Van Nguyen, Nguyen Viet Nhung, Patrick P J Phillips, et al.

    Background: Accessible, accurate screening tests are necessary to advance tuberculosis case finding and early detection in high-burden countries. Methods: We prospectively screened adults with ≥2 weeks of cough at primary health centers in the Philippines, Vietnam, South Africa, Uganda, and India. Participants underwent chest radiography, Cepheid Xpert TB Host Response (Xpert HR) testing, and point-of-care C-reactive protein (CRP) testing (Boditech). Chest radiographs were processed using CAD4TB v7, a computer-aided detection (CAD) algorithm. We assessed diagnostic accuracy against a microbiologic reference standard (sputum Xpert Ultra, culture). Optimal cutoff points were chosen to maximize specificity at 90% sensitivity. Two-test screening algorithms were considered, using (1) sequential negative serial screening (with positive defined as positive on either test) and (2) sequential positive serial screening (with positive defined as positive on both tests). Results: Between July 2021 and August 2022, a total of 1392 participants with presumptive tuberculosis had valid index tests and reference standard results, and 303 (22%) had confirmed tuberculosis. In head-to-head comparisons, CAD4TB v7 showed the highest specificity at 90% sensitivity (70.3% vs 65.1% for Xpert HR [95% confidence interval for absolute difference in specificity, 1.6%–8.9%] and vs 49.7% for CRP [17.0%–24.3%]). Three 2-test screening algorithms met World Health Organization target product profile minimum accuracy thresholds and had higher accuracy than any test alone. At 90% sensitivity, the specificity was 79.6% for Xpert HR–CAD4TB (sequential negative), 75.9% for CRP-CAD4TB (sequential negative), and 73.7% for Xpert HR–CAD4TB (sequential positive). Conclusions: CAD4TB achieves target product profile targets and outperforms Xpert HR and CRP. Combining screening tests further increased accuracy. Clinical Trials Registration. NCT04923958


  • MDA-GAN: Multiscale and Dual Attention Generative Adversarial Network for Bone Suppression in Chest X-Rays

    by Anushikha Singh, Rukhshanda Hussain, Rajarshi Bhattacharya, Brejesh Lall, B.K. Panigrahi, Anurag Agrawal, Balamugesh Thangakunam, D.J. Christopher

    The bone structure in a chest x-ray creates trouble for a radiologist to examine the organs, manifestation of disease, and hidden tiny abnormalities. Bone suppression in chest x-rays allows better examination of lung fields. This has the potential to improve diagnostic accuracy. Dual-energy subtraction imaging is a standard bone suppression technique that delivers a higher dose of radiation and requires specific hardware. This paper proposes a novel multi-scale and dual attention-guided generative adversarial network (MDA-GAN) to transform chest x-rays into bone-suppressed x-rays in an unsupervised manner. We incorporate a spatial attention module to generate attention maps that were further concatenated with the coarsely generated bone segmentation mask. This dual attention is introduced to the generator at multiple scales in between the skip connection of the encoder and decoder layer. The proposed dual attention multi-scale mechanism helps the generator to learn that only bones need to be removed on the chest x-ray without tempering the remaining parts. The proposed MDA-GAN is trained with adversarial loss combined with deep supervised cycle consistency and structure similarity for unpaired training images. We employ supervision heads in all the decoder layers to convert the activation maps into an output comparable to the scaled-down images and minimize the cycle consistency loss in a deep supervised manner. Experiments are conducted on an unpaired dataset including the public and our in-house Indian dataset and results show that incorporating dual attention at multiple scales and deep cycle consistency in translation networks significantly improves the quality of bone-suppressed images. ( https://github.com/rB080/ribsup.git ).


  • Clinical validation of Swaasa® artificial intelligence platform using cough sounds for screening and diagnosis of respiratory diseases

    by Balamugesh Thangakunam, Sujith Chandy, D J Christopher, Narayana Rao Sripada, Charishma Gottipulla, Gowrisree Rudraraju, Kripa Rasquinha, Prasanna Samuel

    Introduction: Analysis of cough sounds has the potential to give a clue to the underlying respiratory disease. The Swaasa® platform using artificial intelligence technology was evaluated to diagnose respiratory diseases. Methods: Patients (age >= 18 years) with respiratory symptoms were recruited into the study. Patient’s cough sound was recorded by a mobile device with Swaasa software. Spirometry was done and clinical diagnosis was taken as reference standard. Variables were analysed in binary form as normal and abnormal. Multi-class outcomes were defined for spirometry patterns classified as obstructive, restrictive or normal, for severity of impairment and for disease conditions such as asthma, COPD, ILD, bronchiectasis etc. Results: We recruited 2179 patients with respiratory diseases and 827 normal individuals. 62% of them were males. The Swaasa platform showed high accuracy in distinguishing normal individuals from those with disease as well as distinguishing normal from abnormal spirometry (Fig 1). The performance was consistent across demographic parameters such as age, gender, and BMI. Its accuracy in differentiating into various patterns of spirometry abnormality (obstructive/restrictive), severity of spirometry abnormalities as well as disease types is sub-optimal. (Fig 2) Conclusion: Swaasa® commends a high level of precision in classifying normal and abnormal conditions across demographic subgroups, indicating its promise as a screening tool. Performance for specific respiratory conditions and disease severity needs further refinement to improve it accuracy.